Nash David T, Nash Stephen D
Syracuse Preventive Cardiology, Syracuse, NY 13202, USA.
Lancet. 2008 Oct 11;372(9646):1335-41. doi: 10.1016/S0140-6736(08)61554-8.
Ranolazine is a new and unique antianginal drug that has been approved for the treatment of chronic stable angina pectoris. The drug is administered as a sustained-release formulation. Although the drug's mechanism of action has not been fully elucidated, current thinking is that ranolazine, a selective inhibitor of late sodium influx, attenuates the abnormalities of ventricular repolarisation and contractility associated with ischaemia. Three randomised trials have shown efficacy for ranolazine in increasing exercise testing or reducing anginal episodes or use of glyceryl trinitrate. Side-effects include dizziness, constipation, nausea, and the potential for prolongation of the QT(c) interval. Ranolazine seems to be a safe addition to current traditional drugs for chronic stable angina, especially in aggressive multidrug regimens.
雷诺嗪是一种新型且独特的抗心绞痛药物，已被批准用于治疗慢性稳定性心绞痛。该药物以缓释制剂形式给药。尽管其作用机制尚未完全阐明，但目前认为，作为晚期钠内流的选择性抑制剂，雷诺嗪可减轻与缺血相关的心室复极和收缩异常。三项随机试验表明，雷诺嗪在增加运动试验、减少心绞痛发作或硝酸甘油使用方面具有疗效。副作用包括头晕、便秘、恶心以及QT(c)间期延长的可能性。对于慢性稳定性心绞痛，雷诺嗪似乎是现有传统药物的一种安全补充，尤其是在积极的多药联合治疗方案中。
